FOLFOX4 in advanced colorectal cancer: a monoinstitutional experience.
OBJECTIVE
Patients included in clinical trials are "selected", and they usually differ from those commonly treated.


METHODS
From 1999 to 2004, in the Medical Oncology Department of Padua (Italy), 70 metastatic colorectal cancers were treated with FOLFOX4.


RESULTS
Our results, compared with those of the registration trial (response rate, duration of response and progression-free survival) appeared lower; overall survival was improved.


CONCLUSIONS
The number of therapeutic regimens more than their type influenced the results.
Boscolo
Giorgia
G
Operative Unit of Medical Oncology, Istituto Oncologico Veneto, Padua, Italy.
Pasetto
Lara Maria
LM
Jirillo
Antonio
A
Monfardini
Silvio
S
D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000473:pathology; D018572:Disease-Free Survival; D004334:Drug Administration Schedule; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D002955:Leucovorin / Q000008:administration & dosage; D008297:Male; D008875:Middle Aged; D009944:Organoplatinum Compounds / Q000008:administration & dosage; D012189:Retrospective Studies; D016019:Survival Analysis; D016896:Treatment Outcome
D009944:Organoplatinum Compounds; D002955:Leucovorin; D005472:Fluorouracil